Clinical trials: Epirubicin
Hepatocellular Carcinoma, Liver Neoplasms
TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC
Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death that ranks sixth in terms of incident cases, with an overall 5 years survival of 18%.
- Conditions
- Hepatocellular Carcinoma, Liver Neoplasms, Digestive System Neoplasms, Sorafenib
- Trial name
- NCT04518852
- Testing
- TACE combined with sorafenib and PD-1 mAb
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Pancreatic Cancer
Cisplatin, Capecitabine, Gemcitabine and Epirubicin or Docetaxel for Patients With Stage III or IV Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin, capecitabine, gemcitabine hydrochloride, epirubicin hydrochloride, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or…
- Trial name
- PACT-9 (NCT00966706)
- Testing
- capecitabine, cisplatin, docetaxel
- Where
- Italy
- Volunteers
- 105 people
- Sponsor
- IRCCS San Raffaele
Breast Cancer Stage II, Breast Cancer Stage III
Adjuvant Palbociclib in Elderly Patients With Breast Cancer
Phase II study to assess the efficacy of the combination of at least 5 year endocrine therapy and 2 year-palbociclib as adjuvant systemic treatment instead of adjuvant chemotherapy followed by endocrine therapy in older patients…
- Trial name
- Appalaches (NCT03609047)
- Testing
- Palbociclib, Docetaxel / cyclophosphamide, doxorubicin/cyclophosphamide
- Where
- 73 sites in Belgium, France and 7 more
- Volunteers
- 366 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as epirubicin, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00753207
- Testing
- epirubicin hydrochloride, lapatinib ditosylate, biomarker analysis
- Where
- 3 sites in Ireland
- Volunteers
- 10 people
- Sponsor
- Cancer Trials Ireland
Multiple Myeloma
Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy
Patients 60 to 70 years of age with newly diagnosed multiple myeloma were prospectively randomized between 4 cycles of anthracycline/dexamethasone-based induction chemotherapy (A1) or only 2 x 4 days of dexamethasone (A2).
- Trial name
- DSMM-II (NCT02288741)
- Testing
- Anthracycline/dexamethasone-based induction chemotherapy, Dexamethasone for control of symptoms, Tumor-reduction chemotherapy and stem cell mobilization
- Volunteers
- 549 people
- Sponsor
- WiSP Wissenschaftlicher Service Pharma GmbH
Adenocarcinoma of the Esophagogastric Junction
Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction
Metabolic and Molecular Response evaluation for the individualization of therapy in adenocarcinomas of the gastroesophageal junction by evaluation of the R0 resection rate for patients with metabolically (ie, according to PET…
- Trial name
- MEMORI (NCT02287129)
- Testing
- Oxaliplatin, Epirubicin, Capecitabine
- Where
- Germany
- Volunteers
- 75 people
- Sponsor
- Technical University of Munich
Haematological Abnormality
The Safety and Efficacy of Jobelyn in the Treatment of Breast Cancer Patients
To determine the effective functionality/potency of Jobelyn as an immunologic and haematologic booster in Breast cancer patients (start-off), thus improving the outlook and the quality of life of such patients generally
- Trial name
- NCT01936064
- Testing
- Jobelyn + Cyclophosphamide-Epirubicin6
- Where
- 2 sites in Nigeria
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Lagos State University
Breast Cancer
Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer
Recent clinical studies showed that triple-negative breast cancer patients (ER-/PR-/HER2-) may benefit more from Capecitabine chemotherapy.
- Trial name
- NCT01642771
- Testing
- 5-Fu/epirubicin/CTX following Docetaxel, Docetaxel/capecitabine followed by XEC
- Where
- 37 sites in China
- Volunteers
- 636 people
- Sponsor
- China Breast Cancer Clinical Study Group
Breast Cancer
Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status
The main objective of this multicenter study will therefore be to evaluate pathologic complete response rates of an anthracycline-based regimen [FEC 100 - TAXOTERE® - HERCEPTIN® - PERTUZUMAB] and a non anthracycline-based regimen…
- Trial name
- NeoTOP (NCT02339532)
- Testing
- FEC100, Docetaxel, Trastuzumab
- Where
- 12 sites in France
- Volunteers
- 86 people
- Sponsor
- UNICANCER
Hepatocellular Carcinoma
TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma
It is an exploratory clinical study aimed to evaluate the efficacy and safety of TACE combined with Lenvatinib in the treatment of patients with BCLC stage B and C HCC.Treatment will continue until the death or intolerable…
- Trial name
- NCT04490694
- Testing
- Lenvatinib, TACE
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Shanghai Zhongshan Hospital
Breast Cancer
Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）
This study is a multi-center, randomized, prospective phase II clinical trial aimed at exploring and evaluating the efficacy of dalpiciclib combined with AI in neoadjuvant treatment for ER strong positive（ER≥50%），HER2-negative…
- Trial name
- NCT06107673
- Testing
- Dalpiciclib, Aromatase inhibitor, Docetaxel injection
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Hebei Medical University Fourth Hospital
Histological or Cytological Confirmed Stage Ⅲ and Ⅳa Thymoma
The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train.
This study for a single-center prospective phase II randomized controlled train to assess the efficacy and safety of Induction therapy on thymoma .Methods patients with thymoma (stage Ⅲ and stage Ⅳa) were treated with 2 cycles of…
- Trial name
- NCT05816694
- Testing
- NAB-Paclitaxel plus Cisplatin, Cisplatin plus Epirubicin plus Cyclophosphamide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peng Liu
Triple Negative Breast Cancer (TNBC)
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer
This is a single-center, single-arm, prospective study enrolling 30 patients with stage II-III triple-negative breast cancer. The neoadjuvant regimen consists of QL1706 combined with carboplatin plus albumin-bound paclitaxel…
- Trial name
- NCT07342283
- Testing
- Immunotherapy combined with chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Affiliated Hospital of Nantong University
Estrogen Receptor Negative, HER2/Neu Negative
Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer
This phase I clinical trial studies the side effects and the best dose of dinaciclib when given together with epirubicin hydrochloride (epirubicin) in patients with metastatic (cancer that has spread to other parts of the body)…
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative
- Trial name
- NCT01624441
- Testing
- Dinaciclib, Epirubicin Hydrochloride, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer
Anthracycline-taxane based chemotherapy regimens are recommended mainly by current guidelines for neoadjuvant application of systemic treatment. The addition of other cytotoxic agents, e.g.
- Trial name
- GeparQuinto (NCT00567554)
- Testing
- epirubicin - cyclophosphamide / docetaxel, epirubicin - cyclophosphamide / docetaxel + bevacizumab, paclitaxel
- Where
- Germany
- Volunteers
- 2,600 people
- Sponsor
- GBG Forschungs GmbH
Breast Cancer, Neoadjuvant Therapy
Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer
The purpose of this clinical trial is to evaluate the efficacy and safety of Utidelone based regimen as neoadjuvant treatment With High-risk Early-stage or Locally Advanced Breast Cancer.
- Trial name
- NCT05983094
- Testing
- Utidelone, Carboplatin, Epirubicin
- Where
- China
- Volunteers
- 181 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Neoplasms, Breast
Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer
This is a prospective, open-label, real-word study evaluating the efficacy and safety of lapatinib in combination with chemotherapy versus trastuzumab in combination with chemotherapy in women with HER2-positive and…
- Trial name
- NCT03273595
- Testing
- Lapatinib, Trastuzumab, Paclitaxel
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xijing Hospital
Carcinoma of Urinary Bladder, Superficial
Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder Cancer
The aim of the study is to test the value of immediate post-operative intravesical instillation of epirubicin in patients with intermediate and high risk non muscle invasive bladder cancer (NMIBC).
- Trial name
- NMIBCIVT (NCT02214602)
- Testing
- Epirubicin
- Where
- Egypt
- Volunteers
- 240 people
- Sponsor
- Mansoura University
Stage III Breast Cancer AJCC V7
Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer
Molecular markers predicting response to dose dense chemotherapy with epirubicin and docetaxel in sequence for locally advanced breast cancer Protocol summary. Principal Investigator Hans P. Eikesdal, Professor, Dept.
- Trial name
- DDP (NCT00496795)
- Testing
- epirubicin/docetaxel sequential
- Where
- Norway
- Volunteers
- 100 people
- Sponsor
- University of Bergen
T-lymphoblastic Lymphoma
A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma
To explore the safety, tolerability, and clinical effects of decitabine combined with Second-line chemotherapy regimens for patients with relapsed or refractory T-lymphoblastic lymphoma.
- Trial name
- NCT03558412
- Testing
- CODOX-M/IVAC, Decitabine
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Mingzhi Zhang